{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:03:04Z","timestamp":1791756184000,"version":"4.3.4"},"reference-count":39,"publisher":"Informa UK Limited","issue":"14","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2024,12,5]]},"DOI":"10.1080\/10428194.2024.2395440","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T07:25:56Z","timestamp":1727162756000},"page":"2163-2172","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria"],"prefix":"10.1080","volume":"65","author":[{"given":"Sara","family":"Zhukovsky","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, University of Utah","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"White","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, University of Utah","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham","place":["Birmingham, USA"]},{"name":"O\u2019Neal Comprehensive Cancer Center, University of Alabama at Birmingham","place":["Birmingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-197X","authenticated-orcid":false,"given":"Oliver","family":"Van Oekelen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-907X","authenticated-orcid":false,"given":"Edward R. Scheffer","family":"Cliff","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women\u2019s Hospital","place":["Boston, USA"]},{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008735"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.336"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1929"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.241"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00405-9"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2019.2019.0061"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001459"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24351"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.17.1889"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90221.x"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1867725"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0272-0"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03984-w"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092147"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.013"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189506"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283723"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17436"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26166"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2021.07.010"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.374"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4658"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018657"},{"key":"e_1_3_6_25_1","unstructured":"U.S Department of Health and Human Services Food and Drug Administration Oncology Center of Excellence Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Cancer clinical trial eligibility criteria: patients with organ dysfunction or prior or concurrent malignancies. Guidance for industry. 2020."},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014635"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.181339"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02567"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01696"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8002"},{"key":"e_1_3_6_32_1","doi-asserted-by":"crossref","unstructured":"Tilly H. F. Morschhauser L. H. Sehn et. al. 2022. \u2018Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma\u2019 N Engl J Med 386: 351\u201363.","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_3_6_33_1","doi-asserted-by":"crossref","unstructured":"Locke F. L. D. B. Miklos C. A. Jacobson et. al. 2022. \u2018Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma\u2019 N Engl J Med 386: 640\u201354.","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00236-3"},{"key":"e_1_3_6_35_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Enhancing the diversity of clinical trial populations\u2014eligibility criteria enrollment practices and trial designs. Guidance for industry. 2020."},{"key":"e_1_3_6_36_1","volume-title":"ALLG MM26\/NORM: novel combinations for orphan myeloma: the NORM platform study master protocol","author":"Quach H.","year":"2022","unstructured":"Quach H. ALLG MM26\/NORM: novel combinations for orphan myeloma: the NORM platform study master protocol. Department of Haematology, St Vincent\u2019s Hospital Melbourne; 2022."},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.2316"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310063"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.8420"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00587-0"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2024.2395440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T14:07:36Z","timestamp":1750082856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2024.2395440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":39,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,12,5]]}},"alternative-id":["10.1080\/10428194.2024.2395440"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2024.2395440","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}